Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 149 No. 4950 (2019)

Position statement on the use of biosimilars in inflammatory bowel disease

  • Emanuel Burri
  • Pascal Juillerat
  • Michel H. Maillard
  • Michael Manz
  • Pierre Michetti
  • Christian Mottet
  • Gerhard Rogler
  • Nadine Zahnd
  • Stephan Vavricka
Cite this as:
Swiss Med Wkly. 2019;149:w20148


Biologics are effective and have a good safety profile in the treatment of inflammatory bowel disease. Biosimilars have recently become available as treatment option. They are biological agents that are highly similar to the original biologic compound in their structure, biological activity, efficacy and safety. This position paper summarises current knowledge on biosimilars and presents its statements on regulatory issues and clinical situation in order to provide clinicians adequate information for them to reach informed and appropriate shared decision-making with their patients.


  1. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–605. doi:.
  2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–25. doi:.
  3. Swiss Agency for Therapeutic Products. Swissmedic Journal. 2015;10. [cited 2019 February 16]; Available from:
  4. Swissmedic. Guidance Document Authorisation Biosimilar. 2018 [cited 2019 February 18]; Available from:
  5. US Food and Drug Administration. Biological Product Definitions. 2017 [cited 2019 February 18]; Available from:
  6. European Medicines Agency. Biosimilars in the EU. 2017 [cited 2019 February 18]; Available from:
  7. Rathore N, Rajan RS. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog. 2008;24(3):504–14. doi:.
  8. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012;28(6):1053–8. doi:.
  9. European Medicines Agency. Assessment Report: Inflectra. EMA/CHMP/589422/2013. 2013 [cited 2019 February 18]; Available from:
  10. European Medicines Agency. Assessment Report: Remsima. EMEA/H/C/002576/0000. 2013 [cited 2019 February 18]; Available from:
  11. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J Crohn’s Colitis. 2014;8(11):1548–50. doi:.
  12. Danese S, Fiorino G, Michetti P. Changes in Biosimilar Knowledge among European Crohn’s Colitis Organization [ECCO] Members: An Updated Survey. J Crohn’s Colitis. 2016;10(11):1362–5. doi:.
  13. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20. doi:.
  14. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–12. doi:.
  15. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci. 2015;60(4):951–6. doi:.
  16. Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(sup1, Suppl 1):35–44. doi:.
  17. Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–12. doi:.
  18. Farkas K, Rutka M, Bálint A, Nagy F, Bor R, Milassin Á, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis - experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–62. doi:.
  19. Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, et al. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. J Crohn’s Colitis. 2016;10(11):1287–93. doi:.
  20. Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. J Crohn’s Colitis. 2016;10(2):133–40. doi:.
  21. Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, et al.; PROSIT-BIO Cohort. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017;23(2):233–43. doi:.
  22. Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al.; NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16. doi:.
  23. Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study. J Crohn’s Colitis. 2017;11(3):297–304.
  24. Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, et al. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci. 2017;62(11):3117–22. doi:.
  25. Moots R, Azevedo V, Coindreau JL, Dörner T, Mahgoub E, Mysler E, et al. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Curr Rheumatol Rep. 2017;19(6):37. doi:.
  26. Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, et al. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. Inflamm Bowel Dis. 2017;23(11):1908–15. doi:.
  27. Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018;24(46):5288–96. doi:.
  28. Ratnakumaran R, To N, Gracie DJ, Selinger CP, O’Connor A, Clark T, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol. 2018;53(6):700–7. doi:.
  29. Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756284818801244. doi:.
  30. Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, et al. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53(6):692–9. doi:.
  31. Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol. 2016;51(9):1062–8. doi:.
  32. Tursi A, Allegretta L, Chiri S, Della Valle N, Elisei W, Forti G, et al. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers. Minerva Gastroenterol Dietol. 2017;63(4):313–8. doi:.
  33. Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, et al.; PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflamm Bowel Dis. 2019;25(3):568–79. doi:.
  34. Schmitz EMH, Boekema PJ, Straathof JWA, van Renswouw DC, Brunsveld L, Scharnhorst V, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47(3):356–63. doi:.
  35. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. doi:.
  36. Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, et al.; SECURE study group. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3(6):404–12. doi:.
  37. Volkers A, Jansen J. Similar Trial - Efficacy of Infliximab-Biosimilar compared to Infliximab-Biological in Patients with Inflammatory Bowel Disease - a Randomized, Controlled, Double-Blind, Phase 4, Noninferiority Trial. United European Gastroenterol J. 2017;5(A307):P0409. Available from:
  38. Hlavaty T, Krajčovičová A, Šturdík I, Letkovský J, Koller T, Tóth J, et al. Biosimilar infl iximab CT-P13 treatment in patients with infl am matory bowel diseases – a one-year, single-centre retrospective study. Gastroenterol Hepatol (N Y). 2016;70(1):27–36. doi:.
  39. Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(sup1, Suppl 1):45–52. doi:.
  40. Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, et al. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade. Clin Gastroenterol Hepatol. 2019. In production. doi:.
  41. Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. Ann Intern Med. 2019;170(2):99–107. doi:.
  42. Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653–69. doi:.
  43. Jorgensen KK, Goll GL, Sexton J, Olsen IC, Bolstad N, Lundin KE, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trial. J Crohn’s Colitis. 2018;12(supplement_1):348–9. doi:.
  44. Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699–707. doi:.
  45. Michetti P. Efficacy of infliximab biosimilars in patients with Crohn’s disease. Lancet. 2017;390(10111):2435. doi:.
  46. Health Canada. Summary Basis of Decision Remsima. [cited 2019 February 18]; Available from:
  47. Health Canada. Summary Basis of Decision Inflectra. [cited 2019 February 18]; Available from:
  48. Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, et al. Traceability of biologicals: present challenges in pharmacovigilance. Expert Opin Drug Saf. 2015;14(1):63–72. doi:.
  49. World Health Organization. Guidance on the use of International Nonproprietary Names (INNs) for pharmaceutical substances. 2017 [cited 2019 February 18]; Available from:
  50. US Food and Drug Administration. Nonproprietary Naming of Biological Products. Guidance for Industry. 2017 [cited 2019 February 18]; Available from:
  51. Grampp G, Felix T. Pharmacovigilance Considerations for Biosimilars in the USA. BioDrugs. 2015;29(5):309–21. doi:.
  52. European Medicines Agency. European Medicines Agency procedural advice for users of the centralised procedure for similar biological medicinal products applications. 2019 [cited 2019 February 19]; Available from:
  53. US Food and Drug Administration. Considerations in Demonstrating Interchangeability With a Reference Product. Guidance for Industry. Draft Guidance. 2017 [cited 2019 February 19]; Available from:
  54. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R ; Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24(3):625–37. doi:.
  55. Planinc A, Dejaegher B, Vander Heyden Y, Viaene J, Van Praet S, Rappez F, et al. Batch-to-batch N-glycosylation study of infliximab, trastuzumab and bevacizumab, and stability study of bevacizumab. Eur J Hosp Pharm Sci Pract. 2017;24(5):286–92. doi:.
  56. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355–63. doi:.
  57. Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346–54. doi:.
  58. Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043–57. doi:.
  59. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7(1):e135. doi:.
  60. Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease. J Gastroenterol. 2017;52(5):535–54. doi:.
  61. Efficacy and safety of infliximab-biosimilar (Inflectra) compared to infliximab-innovator (Remicade) in patients with inflammatory bowel disease in remission: the SIMILAR Trial. [cited 2019 February y14]; Available from:
  62. US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. Guidance for Industry. 2015 [cited 2019 February 16]; Available from:
  63. World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). WHO Expert Committee on Biological Standardization. 2016 [cited 2019 Feburar 18]; Available from:
  64. European Medicines Agency. Guideline on Similar Biological Medicinal Products. CHMP/437/04 Rev 1. 2014 [cited 2019 February 18]; Available from:
  65. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31. doi:.
  66. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385–96. doi:.
  67. Radin M, Sciascia S, Roccatello D, Cuadrado MJ. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. BioDrugs. 2017;31(1):37–49. doi:.
  68. Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial (SIMILAR). [cited 2019 February 19]; Available from:
  69. Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease (CONNECT-IBD)., [cited 2019 February 19]; Available from:
  70. An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission. EU Clinical Trials Register, [cited 2019 February 19]; Available from:
  71. Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8. doi:.
  72. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40–7, quiz 48. doi:.
  73. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64(10):1539–45. doi:.
  74. Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015;29(4):241–58. doi:.
  75. Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X1775035. doi:.
  76. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014;16(1):22–6. doi:.. Correction in: AAPS J. 2015;17(6):1520–1. doi:
  77. Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65(7):1132–8. doi:.
  78. Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, et al. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. Inflamm Bowel Dis. 2019;25(1):172–9. doi:.
  79. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182–97. doi:.
  80. Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn’s Colitis. 2010;4(4):355–66. doi:.
  81. Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al.; OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–21. doi:.
  82. Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn’s Disease: Real-world Experience from a Multicenter Cohort Study. Inflamm Bowel Dis. 2017;23(5):833–9. doi:.
  83. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202. doi:.
  84. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al.; UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375(20):1946–60. doi:.
  85. Pillai N, Dusheiko M, Maillard MH, Rogler G, Brüngger B, Bähler C, et al.; Swiss IBD Cohort Study Group. The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. J Crohn’s Colitis. 2019;13(6):744–54. doi:.
  86. Grand View Research. Biosimilars Market Size, Share & Trends Analysis Report By Product, By Application (Oncology, Growth Hormone, Blood Disorders, Chronic & Autoimmune Disorders), By Region, And Segment Forecasts, 2018 - 2025. Jul 2018 [cited 2019 February 20]; Available from:
  87. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44(4):257–66. doi:.
  88. Generics and Biosimilars Initiative Journal Online. Huge discount on biosimilar infliximab in Norway. [cited 2019 February 19]; Available from:
  89. Peyrin-Biroulet L, Lönnfors S, Roblin X, Danese S, Avedano L. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn’s and Ulcerative Colitis Associations. J Crohn’s Colitis. 2017;11(1):128–33. doi:.
  90. Canadian Agency for Drugs and Technologies in Health (CADTH). International Policies on the Appropriate Use of Biosimilar Drugs Enviromental Scan 2018 [cited 2019 February 19]; Available from:
  91. Manolis CH, Rajasenan K, Harwin W, McClelland S, Lopes M, Farnum C. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration. J Manag Care Spec Pharm. 2016;22(9, Suppl):S3–9. doi:.
  92. Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, et al. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(3):601–6. doi:.
  93. Teeple A, Ellis LA, Huff L, Reynolds C, Ginsburg S, Howard L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35(4):611–7. doi:.

Most read articles by the same author(s)